← Eichor
Study identifier: NCT07727694 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Securing Access to Innovative Molecules in Oncology and Hematology for Children, Adolescents and Young Adults

Condition: Pediatric Cancer  ·  Sponsor: Universitaire Ziekenhuizen KU Leuven

PhaseN/A
Planned participants1600
Who can joinAll sexes, 0 Years to 25 Years
Healthy volunteersNo

About this study

It involves collecting safety and efficacy data, under the actual conditions of use of off label and compassionate use medicines in children and adolescents approved in humans before 2007, using a validated tool (Ennov EDC) and relying on the network recognised pediatric hemato-oncology centers in Belgium and responsible for the organization of Pediatric National tumor boards which discuss each case of relapse in order to define the best therapeutic options.

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (6)

University Hospital AntwerpAntwerp, BelgiumNot Yet Recruiting
Hôpital Universitaire des Enfants Reine Fabiola (HUDERF)Brussels, BelgiumNot Yet Recruiting
Cliniques Universitaires Saint-LucBrussels, BelgiumNot Yet Recruiting
University Hospital GentGhent, BelgiumNot Yet Recruiting
University Hospital LeuvenLeuven, BelgiumRecruiting
CHC MontlégiaLiège, BelgiumNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07727694